However, the higher baseline HbA1c in the PIONEER 3 trial (8.31% in PIONEER 3 compared with 7.96% in PIONEER 4) was felt to be more aligned with target population in Portugal, and to correlate with the large reductions in HbA1c observed in the NMA with oral semaglutide 14 mg, and therefore the PIONEER 3 data were used in the base case analysis
Always label vials with reconstitution date and discard after expiration
To further assess oxidative stress, we quantified circulating 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative DNA damage generated when hydroxyl radicals oxidize guanine residues
Studies including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have demonstrated reduced cardiovascular events in patients with type 2 diabetes
18H06043 and Japan Science and Technology Agency (JST) PRESTO no
TeleWellnessMD is a technology platform that connects patients with licensed healthcare providers